857650-90-9 Usage
Uses
Used in Pharmaceutical Industry:
PF-04136309 is used as a PDE9A inhibitor for its potential therapeutic effects in treating neurological and psychiatric disorders such as Alzheimer's disease, schizophrenia, and cognitive impairment.
Used in Neurological Disorders Treatment:
PF-04136309 is used as a cognitive function enhancer and neuroinflammation reducer in preclinical studies for the treatment of Alzheimer's disease and other cognitive impairments.
Used in Psychiatric Disorders Treatment:
PF-04136309 is used as a regulator of dopamine and glutamate signaling in the brain for its potential therapeutic effects in treating schizophrenia and other neuropsychiatric conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 857650-90-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,7,6,5 and 0 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 857650-90:
(8*8)+(7*5)+(6*7)+(5*6)+(4*5)+(3*0)+(2*9)+(1*0)=209
209 % 10 = 9
So 857650-90-9 is a valid CAS Registry Number.
857650-90-9Relevant academic research and scientific papers
A METHOD OF TREATING LIVER FIBROSIS
-
, (2012/09/11)
The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention
3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
-
Page/Page column 22, (2008/06/13)
The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
